Pfizer 2021, 2022 COVID-19 Vaccine Sales To Hit $65bn •US Regulators To Okay Administering Vaccine To 5-Year-Old Children
Pfizer Inc (PFE.N) has declared that it is expecting to make $36 billion from the COVID-19 vaccine it developed with German partner, BioNTech (22UAy.DE) and another $29 billion in sales in 2022.
The expected $65 billion from the two-year sales, according to a report by Reuters, on Tuesday, would automatically top analyst’s estimates for both years.
This was as it has been reported that the US regulators may likely give the green light to begin administering the vaccine to children from ages five to 11, starting from tomorrow, Wednesday.
Pfizer Inc (PFE.N), according to the report, is seeking to sign more deals with countries, which could drive sales of the vaccine, even higher, in 2022.
“It has the capacity to produce four billion doses in 2022 and has based its projections on sales of 1.7 billion doses,” the report stated.
The report further stated: “Pfizer’s COVID-19 vaccine was the first shot to receive U.S. authorization last year, and U.S. regulators are likely to give the green light to begin administering the vaccine to children ages five to 11, as soon as Wednesday.
“Pfizer, which equally splits gross profit for the shot in most of the world with BioNTech, raised its revenue forecast for the vaccine to $36 billion for 2021, suggesting that the shot will account for as much as 44 per cent of its total sales for the year.
“Wall Street on average expected sales of $35.44 billion this year from the vaccine and $22.15 billion for 2022, according to eight analysts polled by Refinitiv.
“Sales of the vaccine, called Comirnaty, have vastly outpaced those of rivals Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N), which are struggling with production snags and safety concerns.
“The company is on track to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it plans to make this year.”
Mizuho analyst, Vamil Divan said; “The longer-term revenues that they may be able to generate from Comirnaty remains unknown and will be determined in part by how the pandemic evolves, as well as competitive dynamics within that market.”
Reuters also reported that the vaccine brought in sales of $13 billion in the third quarter, just Pfizer’s shares rose by 2.7 per cent in morning trading, on Tuesday.
